Business
Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology had better glucose outcomes than those using traditional fingersticks. Improvements were achieved through participant-led self-management, guided by real-time CGM insights. Findings were presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (AT
About this update from Abbott Laboratories
[{"type":"list","items":[{"val":[{"type":"text","content":"U.K. FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks 1,2","length":192,"tagName":"p"}]},{"val":[{"type":"text","content":"Improvements were participant-led, using real-time glucose readings to guide everyday decisions","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Complementary Italian study reported similar improvements, reinforcing the value of Libre technology for this population3","length":121,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":408,"olType":false},{"type":"text","content":"ABBOTT PARK, Ill., March 12, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology had better glucose outcomes than those using traditional fingersticks. Improvements were achieved through participant-led self-management, guided by real-time CGM insights. Findings were presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).","length":558,"tagName":"p"},{"type":"text","content":"About 63 million people worldwide rely on insulin to manage Type 2 diabetes4, but real-world studies show only 18%–30% of those using basal insulin are reaching their HbA1c goals.5,6 This gap contributes to an estimated $217 billion in annual diabetes healthcare costs, indicating millions of people still need support to reach healthy glucose ranges.7 The FreeDM2 randomized controlled trial was designed to determine whether real-time continuous glucose monitoring can help people using basal insulin improve their glucose management.","length":536,"tagName":"p"},{"type":"text","content":"Conducted across 24 clinical sites in the U.K. and involving 303 participants, the study compared the effectiveness of CGM with traditional self‑monitoring of blood glucose (SMBG) in people with Type 2 diabetes using basal insulin.8","length":232,"tagName":"p"},{"type":"text","content":"Significant improvements through self-managementAt four months, participants using an Abbott FreeStyle Libre system for continuous glucose monitoring had a significantly greater redu...